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LETTERS TO THE EDITOR
Sickle cell patients are characterized by a
reduced glycocalyx volume
The glycocalyx is an important anti-inflammatory
and anti-adhesive barrier at the luminal side of
endothelial cells. Glycocalyx volume was significant-
ly reduced in sickle cell patients (HbSS/HbSβ0–tha-
lassemia median 0.47L, IQR 0.27-0.66, HbSC/HbSβ+-
thalassemia 0.23L, 0.0-0.58) compared with controls
(1×109L, 0.52-1.77) (p=0.03). Reduced glycocalyx
may be a new factor in the pathophysiology of sickle
cell disease. 
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Endothelial activation and dysfunction play a central role
in the pathophysiology of sickle cell disease (SCD) related
vaso-occlusion.1 The extent of endothelial activation was
recently shown to be related to the presence of severe dis-
ease related manifestations such as pulmonary hyperten-
sion.2
New insights into endothelial biology have demonstrat-
ed that, in the quiescent state, the endothelium is shielded
from circulating blood cells and proteins by the glycocalyx,
a highly hydrated cell free mesh of membrane-associated
proteoglycans, glycosaminoglycans, glycoproteins and gly-
colipids located at the endothelial surface.3 With a thickness
ranging from 0.5-3.0 µm, it exceeds the intra-luminal size
of most endothelial adhesion molecules, thereby potential-
ly preventing interactions of the endothelium with blood
constituents.4 Glycocalyx volume is regulated by numerous
factors and rapid degradation has been observed during
ischemia, hypoxia, and exposure to both tumor necrosis
factor alpha and oxidized low density lipoproteins.5-8
Therefore, in conditions of ischemia and inflammation,
which occur continuously in SCD, a reduced glycocalyx
volume may facilitate interactions of activated endothelial
cells with blood cells and proteins. Given the important
role of endothelial activation in the pathophysiology of
SCD related vaso-occlusion, we set out to investigate
whether the glycocalyx volume is reduced in patients with
SCD.
Consecutive adult sickle cell patients (HbSS, HbSβ0/+-tha-
lassemia or HbSC, confirmed with high performance liquid
chromatography) visiting the out-patient clinic of the
Academic Medical Center in Amsterdam were eligible for
inclusion. Exclusion criteria were a history of an acute vaso-
occlusive episode (painful crisis, acute chest syndrome,
stroke, splenic- or liver sequestration) or blood transfusion
4 weeks prior to sample collection; diabetes mellitus; he-
morrhagic retinopathy; hemorrhagic disorders or hyperten-
sion (systolic and diastolic blood pressure >140 mm Hg or
>90 mm Hg respectively). For data analysis patients with
the most severe genotypes (HbSS and HbSβ0-thalassemia)
were grouped together, as were patients with the relative-
ly milder genotypes (HbSC and HbSβ+-thalassemia). Age,
sex and race matched subjects, heterozygous for hemoglo-
bin C or S (HbAS and HbAC, confirmed by high perform-
ance liquid chromatography), served as healthy controls.
All patients and controls gave written informed consent
and this study was approved by the Medical Ethics
Committee of the Academic Medical Center in Amsterdam
and carried out in accordance with the principles of the
Declaration of Helsinki. 
The glycocalyx volume was estimated by comparing cir-
culating blood volume with the intravascular distribution
volume of a glycocalyx-permeable tracer such as neutral
dextran 40 (molecular weight 40 kDa).9 To determine the
intravascular distribution volume of dextran 40, the con-
centration of dextran 40 at the time of injection was esti-
mated by exponential fitting of the measured dextran 40
concentrations. The intravascular distribution volume of
labeled, autologous erythrocytes was used to quantify cir-
culating blood volume.10 Labeled erythrocytes were measured
using a flowcytometry (FACSCalibur; Becton Dickinson,
Mountain View, CA, USA), during which at least 100,000
cells were counted. Circulating plasma volume was calcu-
lated from circulating erythrocyte volume (Vrbc) and 
systemic hematocrit (Hsys) by the following formula: 
circulating plasma volume = ([1 – Hsys] x Vrbc)/Hsys.10
Data were expressed as medians with corresponding
interquartile ranges (IQR). Between group differences were
tested with the Kruskal Wallis Test. For correlation studies
the Spearman Rank correlation coefficient was determined.
p-values ″0.05 were considered statistically significant.
Statistical analysis was performed using the SPSS 12.0.2
(SPSS Inc, Chicago, IL, USA). Twenty sickle cell patients (9
HbSS, 3 HbSβ0-thalassemia, 6 HbSC and 2 HbSβ+-tha-
lassemia) and 10 healthy controls (9 HbAS, 1 HbAC) were
included in the study. Patient and control characteristics
and laboratory data are presented in Table 1. Four patients
in the severe genotype group used hydroxyurea. 
The glycocalyx volume was statistically significantly lower
in patients compared with controls (Figure 1). There were no
statistically significant differences in blood volume, plasma
volume and dextran distribution volume between the
groups. Glycocalyx volume did not differ between patients
that used hydroxyurea and those who did not.
New insights into endothelial biology have demonstrated
an important role of the glycocalyx in vascular homeosta-
sis.3 Loss of glycocalyx by acute hyperglycemia in healthy
controls results in endothelial dysfunction and is associated
with microvascular damage in type 1 diabetes.9,11 In the
present study, we demonstrated that the glycocalyx vol-
ume is significantly reduced in patients with SCD and is
comparable to that reported in patients with diabetes mel-
litus type 1.9,11 Contrary to expectations, the median glyco-
Table 1. Baseline characteristics.
Genotype
Characteristics HbSS/ HbSC/
HbSβ0-thal HbSβ+-thal Controls
N 12 (9/3) 8 (6/2) 10
Age (y) 33 (22-43) 31 (26-39) 40 (27-42)
Male/Female 1/11 3/5 3/7
Systole (mmHg) 110 (104-121) 114 (101-118) 121 (112-139)
Diastole (mmHg) 68 (65-78) 70 (56-76) 82 (77-92)
Body mass index 21 (20-24) 23 (22-26) 27 (23-31)
Blood parameters
Hemoglobin (mmol/L) 5.5 (5.1-6.0) 7.1 (6.3-7.8) 8.5 (7.3-8.9)
Reticulocytes (%) 8.8 (6.3-11) 2.8 (2.1-2.9) 1.1 (0.9-1.7)
Leukocyte count (x109/L) 8.0 (6.5-10.1) 7.0 (5.7-8.2) 7.2 (3.3-9)
Lactate dehydrogenase (U/L) 385 (289-570) 220 (181-235) 171 (164-181)
Fetal hemoglobin (%) 9.4 (4.2-14.7) 2.4 (0.5-3.6) 0.5 (0.5-0.5)
All numbers are medians (interquartile range). 
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calyx volume was slightly higher (non-significant) in
HbSS/HbSβ0-thal patients compared with HbSC/HbSβ+-thal
patients. This may be caused by the relatively low number
of HbSC/HbSβ+-thal patients and/or by the inclusion of rel-
atively severely affected HbSC/HbSβ+-thal patients. 
Studies in humans and animals have shown that the gly-
cocalyx volume is reduced after episodes of experimental
ischemia, hypoxia and after exposure to oxidized low-den-
sity lipoproteins and oxygen radicals. Acute hyperglycemia,
which is associated with the formation of reactive oxygen
species, results in a severe loss of glycocalyx volume in
healthy volunteers.12 Continuous tissue ischemia and reper-
fusion is associated with the formation of reactive oxygen
species in SCD which may result in a reduced glycocalyx
volume. A reduction of the glycocalyx could have several
important consequences in SCD. Adhesive interactions
between sickle red blood cells, leukocytes and the activated
endothelium play a key role in the initiation and propaga-
tion of SCD-related vaso-occlusion. A reduced glycocalyx
volume may facilitate such interactions. 
In conclusion, we demonstrate a reduced glycocalyx 
volume in sickle cell patients during the steady state 
suggesting a disrupted endothelial environment. We
hypothesize that glycocalyx perturbation could be a new
factor of bi-directional importance in the complex patho-
physiology of SCD, since glycocalyx volume reductions can
both result from and contribute to vaso-occlusion. 
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Figure 1. Glycocalyx volume in sickle cell patients and healthy
controls. The glycocalyx volume differed significantly between the
HbSS/HbS‚0-thal group [median 0.47 liters (L), IQR 0.27-0.66],
the HbSC/HbSβ0-thal group (0.23L, IQR 0.0-0.58) and healthy
controls (1.09L, IQR 0.52-1.77) (Kruskal Wallis p=0.025). Bars
represent medians and error bars the 75th percentile.
2
1
0
Controls
Gl
yc
oc
al
yx
 v
ol
um
e 
(L
)
HbSS/Sβ0-thal
Phenotype
HbSC/Sβ0-thal
